Lakshman Segar, Ph.D

Clinical and Administrative Pharmacy, Augusta
Associate Professor

Clinical and Administrative Pharmacy, Augusta

  • Education

    Associate Professor, University of Georgia 2011-Present

    Research Pharmacologist, VA Medical Center 2011-Present

    Core Lab Director, GCRC, Heart and Vascular Institute, Penn State University 2008-2010

    Assistant Professor, Penn State University 2000-2011

    Research Associate, Penn State University 1998-2000

    Postdoctoral Fellow, University of British Columbia 1996-1998

    Postdoctoral Fellow, University of Saskatchewan 1994-1996

    Graduate Teaching Assistant, University of Saskatchewan 1992-1993

    Ph.D. Pharmacology, University of Saskatchewan 1990-1994

  • Honors, Awards, and Achievements

    Postdoctoral Fellowship award, Health Services Utilization and Research Commission, Saskatoon, Saskatchewan, Canada

    Graduate Scholarship, College of Graduate Studies and Research, University of Saskatchewan, Saskatoon, Saskatchewan, Canada (1990-1994)

    Member, Editorial Board of the Journal of Pharmacology and Clinical Toxicology

  • Research Interests

    Diabetic vascular complications: Atherosclerosis, restenosis after angioplasty, vascular injury, dyslipidemia, smooth muscle cell phenotype, cell proliferation, cell differentiation, signal transduction mechanisms, platelet-derived growth factor receptor signaling, insulin receptor signaling, and glucose transporters.

    Diabetic retinopathy: Neurovascular complications, retinal ganglion cells, retinal endothelial cells, cell survival, apoptosis, signal transduction mechanisms, platelet-derived growth factor receptor signaling, and insulin receptor signaling.

    Fatty liver disease: dysregulated fatty acid metabolism / mitochondrial oxidative metabolism in metabolically compromised conditions such as alcoholic liver disease, obesity, and diabetes.

  • Selected Publications

    Fairaq, A., Shawky, N. M., Osman, I., Pichavaram, P. and Segar, L.  AdipoRon, an adiponectin receptor agonist, attenuates PDGF-induced VSMC proliferation through inhibition of mTOR signaling independent of AMPK: implications toward suppression of neointimal hyperplasia.  Pharmacol Res. 119: 289-302; 2017.

    Shawky, N. M. and Segar, L.  Sulforaphane inhibits platelet-derived growth factor-induced vascular smooth muscle cell proliferation by targeting mTOR/p70S6kinase signaling independent of Nrf2 activation.  Pharmacol Res. 119: 251-264; 2017.

    Osman, I., Poulose, N., Ganapathy, V. and Segar, L.  High fructose-mediated attenuation of insulin receptor signaling does not affect PDGF-induced proliferative signaling in vascular smooth muscle cells.  Eur J Pharmacol. 791: 703-710; 2016.

    Shawky, N.M., Pichavaram, P., Shehatou, G.S.G., Suddek, G.M., Gameil, N.M., Jun, J.Y. and Segar L.  Sulforaphane improves dysregulated metabolic profile and inhibits leptin-induced VSMC proliferation: implications toward suppression of neointima formation after arterial injury in western diet-fed obese mice.  J Nutr Biochem. 32: 73-84; 2016.

    Segar, L.  Letter to the Editor: Comment on “SGLT2 Inhibitors May Predispose to Ketoacidosis” by Taylor S.I., et al.  J Clin Endocrinol Metab. 101: L27-L28; 2016.

    Osman, I. and Segar, L.  Pioglitazone, a PPARγ agonist, attenuates PDGF-induced vascular smooth muscle cell proliferation through AMPK-dependent and AMPK-independent inhibition of mTOR/p70S6K and ERK signaling.  Biochem Pharmacol. 101: 54-70; 2016.

    Pyla, R., Pichavaram, P., Fairaq, A., Park, M.A., Kozak, M., Kamath, V., Patel, V.S. and Segar L.  Altered energy state reversibly controls smooth muscle contractile function in human saphenous vein during acute hypoxia-reoxygenation: Role of glycogen, AMP-activated protein kinase, and insulin-independent glucose uptake.  Biochem Pharmacol. 97: 77-88; 2015.

    Pyla, R, Osman, I., Pichavaram, P., Hansen, P. and Segar, L.  Metformin exaggerates phenylephrine -induced AMPK phosphorylation independent of CaMKKbeta and attenuates contractile response in endothelium-denuded rat aorta.  Biochem Pharmacol. 92: 266-279; 2014.

    Pyla, R, Poulose, N., Jun, J.Y. and Segar, L.  Expression of conventional and novel glucose transporters, GLUT1, -9, -10, -12, in vascular smooth muscle cells.  Am J Physiol:Cell Physiol. 304: C574-C589; 2013.

    Jun, J.Y., Ma, Z., Pyla, R. and Segar, L.  Leptin treatment inhibits the progression of atherosclerosis by attenuating hypercholesterolemia in type 1 diabetic Ins2+/Akita:apoE-/- mice.  Atherosclerosis 225: 341-347; 2012.

    Jun, J.Y., Ma, Z. and Segar, L.  Spontaneously diabetic Ins2+/Akita:ApoE-deficient mice exhibit exaggerated hypercholesterolemia and atherosclerosis.  Am J Physiol:Endocrinol Metab. 301: E145-E154; 2011.

    Zhao, Y., Biswas, S.K., McNulty, P.H., Kozak, M., Jun, J.Y. and Segar, L.  PDGF-induced vascular smooth muscle cell proliferation is associated with dysregulation of insulin receptor substrates.  Am J Physiol:Cell Physiol. 300: C1375-C1385; 2011.

    Biswas, S.K., Zhao, Y., Nagalingam, A., Gardner, T.W. and Sandirasegarane, L.  PDGF- and Insulin/IGF-1-specific distinct modes of Class IA PI 3-kinase activation in normal rat retinas & RGC-5 retinal ganglion Cells.  Invest Ophthal Vis Sci. 49: 3687-3698; 2008.

    Antonetti, D.A., Barber, A.J., Bronson, S.K., Freeman, W.M., Gardner, T.W., Jefferson, L.S., Kester, M., Kimball, S.R., Krady, J.K., LaNoue, K.F., Norbury, C.C., Quinn, P.G., Sandirasegarane, L. and Simpson, I.A..  Diabetic retinopathy: Seeing beyond glucose-induced microvascular disease.  Diabetes 55: 2401-2411; 2006.

    Reiter, C.E.N., Wu, X., Sandirasegarane, L., Nakamura, M., Gilbert, K.A., Singh, R.S.J., Fort, P.E., Antonetti, D.A. and Gardner, T.W.  Diabetes reduces basal retinal insulin receptor signaling:  Reversal with systemic and local insulin.  Diabetes 55: 1148-1156; 2006.

    Stahl, J.M., Sharma, A., Cheung, M., Zimmerman, M., Cheng, J.Q., Bosenberg, M.W., Kester, M., Sandirasegarane, L. and Robertson, G.P.  Deregulated Akt3 activity promotes development of malignant melanoma.  Cancer Res. 64: 7002-7010; 2004.

    Reiter, C.E.N., Sandirasegarane, L., Wolpert, E.B., Klinger, M., Simpson, I.A., Barber, A.J., Antonetti, D.A., Kester, M. and Gardner, T.W.  Characterization of insulin signaling in rat retina in vivo and ex vivo.  Am J Physiol:Endocrinol Metab. 285: E763-E774; 2003.

    Bourbon, N., Sandirasegarane, L. and Kester, M.  Ceramide-induced inhibition of Akt is mediated through PKCzeta: implications for growth arrest.  J Biol Chem. 277: 3286-3292; 2002.

    Charles, R., Sandirasegarane, L., Yun, J., Bourbon, N., Wilson, R., Rothstein, R.P., Levison, S. and Kester, M.  Ceramide-coated balloon catheters limit neointimal hyperplasia following stretch injury in carotid arteries.  Circ Res. 87: 282-288; 2000.

    Sandirasegarane, L., Charles, R., Bourbon, N. and Kester, M.  NO regulates PDGF-induced activation of PKB but not ERK in A7r5 cells: implications for vascular growth arrest.  Am J Physiol:Cell Physiol. 279: C225-C235; 2000.

  • Grant Support

    R.C. Wilson Pharmacy Fund – UGA College of Pharmacy Foundation Fund
    (01/2018-12/2018)

    Grant-In-Aid award from NIH/NHLBI (R01 Grant, 08/2010-11/2017)

    Grant-In-Aid awards from National Diabetes Research funding agencies (NIH/NIDDK-R21 Grant, 09/2005-06/2008; JDRF-Regular Research Grant, 08/2005-07/2009; and ADA-Innovation Award)

    Beginning Grant-In-Aid awards from American Heart Association, Pennsylvania-Delaware Affiliate (07/1999-06/2002; 07/2002-12/2004)